10.04.18 12:41

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.

Wirsching et al., Ann Oncol. [in press]

Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Caparrotti F, von Moos R, Riklin C, Felsberg J, Roth P, Jones DTW, Pfister S, Rushing EJ, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, Weller M.

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.

Ann Oncol. 2018 Apr 10. doi: 10.1093/annonc/mdy120. [Epub ahead of print] PubMed ID: 29648580

 

Further Information:

undefinedPubMed

undefinedGuido Reifenberger

Verantwortlich für den Inhalt: E-Mail sendenNeuroscience Network Düsseldorf